1,N⁶-etheno-9-methyladenine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1,N⁶-etheno-9-methyladenine
• 英文别名: 3-methyl-1,N⁶-ethenoadenine；9-methyl-1,N⁶-ethenoadenine；3-methylimidazo[2,1-i]purine；3-Methylimidazo[2,1-f]purine
• 化学式: C₈H₇N₅
• 分子量: 173.177
• InChiKey: OMPOPGSMAWCHBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9-甲基腺嘌呤 、 chloromalonaldehyde 以 水 为溶剂， 生成 1,N⁶-etheno-9-methyladenine 、 1,N⁶-etheno-11-formyl-9-methyladenine
  参考文献：
  名称：

  Reactions of Adenosine with Bromo- and Chloromalonaldehydes in Aqueous Solution: Kinetics and Mechanism

  摘要：

  Reactions of adenosine nucleosides with halogen substituted acetaldehydes and malonaldehydes have been studied and pseudo first-order rate constants have been determined. All the reactions yield 1,N-6-etheno adducts, and with malonaldehydes, in addition to this, 11-formyl-1,N-6-etheno adducts are also formed. Particular attention has been paid to the formation of the formyletheno products. The results obtained suggest that the reactions of adenine base with halogenated acetaldehydes and malonaldehydes are basically similar. It also seems that in reactions of halomalonaldehydes with adenosine, the etheno and formyletheno products are formed through the same initial reaction pathway i. e. the attack of the B-amino group of the adenine base at the carbonyl carbon atom of the aldehyde.

  DOI：

  10.1002/1099-0690(200006)2000:12<2315::aid-ejoc2315>3.0.co;2-g

文献信息

• SULFAMIDE AND SULFAMATE INHIBITORS OF hHint1
  申请人：Wagner Carston R.

  公开号：US20180065965A1

  公开（公告）日：2018-03-08

  Embodiments provide, among things, compounds of the formula I and methods for using such compounds to reduce pain (e.g., neuronal pain), treat a mammal's addiction to nicotine or anti-pain drugs, and increase a mammal's sensitivity to drugs that bind MOR or NMDAR.

  实施例提供了一些化合物I的公式和使用这些化合物来减轻疼痛（例如神经性疼痛）、治疗哺乳动物对尼古丁或镇痛药物的成瘾，并增加哺乳动物对结合MOR或NMDAR的药物的敏感性的方法。
• Synthesis of nucleoside 5′-triphosphates and their derivatives
  申请人：Huang Zhen

  公开号：US11072624B2

  公开（公告）日：2021-07-27

  Disclosed are nucleoside 5′-triphosphates modified at the α, (β, and/or γ phosphate to substitute one or more of the phosphate oxygen atoms with a borano, seleno, and/or thio group. Derivatives and pharmaceutically acceptable salts are also contemplated herein. Also disclosed are processes for preparing nucleoside 5′-triphosphates. Non-limiting, exemplary processes can include first reacting salicyl phosphorochloridite with a pyrophosphate reagent to provide P2, P3-dioxo-P1-(salicyl) cyclotriphosphite, and then reacting P2, P3-dioxo-P1-(salicyl) cyclotriphosphite with a nucleoside, followed by oxidation of the nucleoside-phosphite intermediate and hydrolysis to form the modified nucleoside 5′-triphosphate. Nucleoside 5′-triphosphates can be useful in nucleic acid replication, transcription, and translation. Processes disclosed herein are not limited to nucleoside 5′-triphosphates having a native base moiety, such as 9-adeninyl, 1-cytosinyl, 9-guaninyl, 1-thyminyl, or 1-uracilyl, and are also effective for the preparation of nucleoside 5′-triphosphates having a modified nucleobase or unnatural nucleobase.

  所公开的核苷 5′-三磷酸酯是在α、β和/或γ磷酸处进行修饰，用硼、硒和/或硫基取代一个或多个磷酸氧原子。本文还考虑了衍生物和药学上可接受的盐。还公开了制备核苷 5′-三磷酸酯的工艺。非限制性的示例性工艺可包括首先使水杨基亚磷酸与焦磷酸试剂反应以提供 P2、P3-二氧代-P1-（水杨基）环三磷酸酯，然后使 P2、P3-二氧代-P1-（水杨基）环三磷酸酯与核苷反应，接着氧化核苷-亚磷酸中间体并水解以形成修饰的核苷 5′-三磷酸酯。核苷 5′-三磷酸酯可用于核酸复制、转录和翻译。本文所揭示的工艺并不局限于具有原生碱基（如 9-腺嘌呤基、1-胞嘧啶基、9-鸟嘌呤基、1-硫嘌呤基或 1-尿嘧啶基）的核苷 5′-三磷酸酯，而且对于制备具有修饰核碱基或非天然核碱基的核苷 5′-三磷酸酯也是有效的。
• Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives
  申请人：Huang Zhen

  公开号：US20130158249A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of nucleoside 5′-triphosphates of formula (I), or derivatives thereof, or pharmaceutically acceptable salts of said nucleoside 5′-triphosphates or said derivatives, wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R 1 is H or OH, R 2 is H or OH, X is independently selected from the group consisting of O, S and Se; and Y is independently selected from the group consisting of O, B (borano, or BH 3 ), S, and Se. Also disclosed are processes of preparing the compounds of formula (I), said process comprising steps according to Scheme A:
• FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME
  申请人：MARS, INCORPORATED

  公开号：US20180168208A1

  公开（公告）日：2018-06-21

  A flavor composition comprising at least one nucleotide derivative and/or at least one transmembrane compound that modulates, increases and/or enhances the activity of an umami receptor is provided that can be used to enhance the umami taste and/or palatability of food products. In certain, non-limiting embodiments, the flavor composition comprises at least one nucleotide derivative and/or at least one transmembrane compound, optionally at least one nucleotide, optionally at least one first amino acid, optionally at least one second amino acid.
• PRMT5 INHIBITORS
  申请人：Lupin Limited

  公开号：US20220315589A1

  公开（公告）日：2022-10-06

  The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.